Imugene secures A$2.7m R&D tax refund to advance cancer pipeline

Imugene ( (AU:IMU) ) has provided an announcement.

Imugene Limited has received an A$2.74 million research and development tax refund from the Australian Government’s R&D Tax Incentive program for the 2025 financial year. The non-dilutive funding, which includes interest, strengthens the company’s cash position and will support the continued clinical development of its immuno-oncology pipeline at a pivotal time following a recent U.S. FDA meeting and positive clinical results, potentially reinforcing its position in the competitive cancer therapy space.

This refund underscores the importance of government incentives in sustaining high-cost, high-risk oncology research and may help Imugene progress its CAR T and oncolytic virotherapy programs without immediately resorting to additional capital raising. For shareholders and other stakeholders, the payment provides incremental financial flexibility as the company advances toward potential value-inflection milestones in its clinical trials.

The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.24 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited is a Sydney-based, clinical-stage immuno-oncology company developing novel immunotherapies that activate the immune system to treat and eradicate tumours. Its pipeline includes the off-the-shelf CAR T cell therapy azer-cel targeting CD19 for blood cancers, as well as oncolytic virotherapies designed to treat a range of cancers, often in combination with standard of care drugs and emerging immunotherapies.

Average Trading Volume: 1,369,802

Technical Sentiment Signal: Sell

Current Market Cap: A$80.38M

Learn more about IMU stock on TipRanks’ Stock Analysis page.